Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 July 2021 | Story Leonie Bolleurs | Photo Supplied
Katlego Mpoihi says the Engaged Learning Festival equipped him with skills that changed his life in such a way that he could build his own business and provide employment for others. The festival is one of the initiatives of the Directorate Community Engagement to benefit the community, an initiative that also supports Mandela Day.

In celebrating Mandela Day, Bishop Billyboy Ramahlele, Director of the Directorate Community Engagement at the University of the Free State (UFS), believes that when we were born, all of us were clinching a fist holding something in our palms. “As we grew up, we discovered that what we were holding in our palms were our talents and gifts. We therefore exist to unfold our palms and share what we are holding. I challenge each of us to open our palms, stretch out our hands, and share what we are holding with those who are in need.”

It is also with this sentiment that the university, through its Engaged Citizenship programme – which is part of Engaged Scholarship – mobilises and trains communities to take charge of their own lives and development. Bishop Ramahlele describes engaged scholarship as using academic scholarship and professional expertise at the UFS with the intentional purpose to benefit the community. 

In the coming year, Community Engagement will pursue strategic partnerships with government departments at all levels to address the goals of the National Development Plan. The university will also continue to create opportunities for staff and students to engage in the development of communities. “We will ensure that all our staff and students contribute to building social cohesion in our communities by bridging economic, social, and cultural gaps within society,” says Bishop Ramahlele. 

Community Engagement is involved in more than 70 service-learning modules annually, and the university contributes no less than R9 million to set positive change in motion in the community. Some of the many programmes and organisations where an estimated 3 000 students spend at least 127 000 hours, include the Association for People with Disabilities, Bloemshelter, the Trompsburg Clinic and schools, and the Tshepo Foundation. 

Engaged Learning Festival, a beacon of hope

One initiative that stands out, is the annual Engaged Learning Festival

Bishop Ramahlele states that for the past five years, the university has organised and hosted the festival presented in partnership with non-governmental organisations, business, higher education institutions, and government departments.
 
“The festival, which is at the end of every year, runs over three days, with at least 50 different skills presented to about 1 500 attendants. In addition, the university trains no less than 400 people, including the youth, women, and the unemployed, in different skills that will enable them to create jobs for themselves through our ‘Building Social Cohesion through Enterprise Development Programme’,” he proudly adds. 

Despite the fact that the last festival was presented in 2019 due to the COVID-19 pandemic, the positive results of this event continue to impact people’s lives for the better. What comes to mind is the success story of 31-year-old Katlego Mpoihi, who attended the Engaged Learning Festival in 2016.

Mpoihi, who learned about the event at one of the Directorate Community Engagement’s training sessions in Thaba ‘Nchu, says before he left to attend the festival, he had no skills. However, he left his home dreaming about many opportunities for skills development.

“The festival did not disappoint me.”

“I knew nothing when I arrived there, nevertheless, in the three days of the event I learned furniture manufacturing skills, such as carpentry and upholstery that later allowed me to start making headboards, cupboards, pedestals, TV stands, and upholstering.”

“The Engaged Learning Festival changed my life. I feel better about myself now that I can stand on my own.”

“In the five years since I attended the festival, I registered my business, Golukisa Trading. After posting photos of my work on social media, the orders started to come in. With the profit I made, I bought more equipment and expanded my business to installing ceilings, tiles, floors, and walls.”

“Later, I was in the position to help others by creating employment and developing the skills of my staff. Two of the persons I taught started their own business,” says a successful Mpoihi who also managed to buy a car and land for himself.

Mpoihi later also attended training sessions on entrepreneurship, offered by the Directorate Community Engagement. “He is now playing an important role in training other youths and the unemployed during our workshops,” says Bishop Ramahlele. 

Giving back to ensure a better tomorrow for all

Although successful, he keeps on dreaming. “My biggest vision for the future is to open a factory where I can manufacture all types of furniture from scratch. I also see myself spreading my wings beyond the Free State borders, not only creating employment but also opportunities for people to open their own businesses,” says Mpoihi, who is planning on giving back in a big way. 

Was this not also what the late President Mandela had in mind – for us to recognise our individual power so that we can change the world around us?

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept